Market Place
Sourcing Support
All News #Library
Biotech
Hookipa, Having Sold Off Vaccines to Gilead, Opts to Wind Down
21 Jul 2025 //
FIERCE BIOTECH
Gilead pays partner Hookipa $10M for HBV, HIV vaccines
23 May 2025 //
FIERCE BIOTECH
HOOKIPA Completes Enrollment For Phase 1b HB-500 HIV Trial
30 Jan 2025 //
GLOBENEWSWIRE
Hookipa Pharma’s Eseba-vec Highlighted in SITC Late-Breaker
11 Nov 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Reports Q2 2024 Results And Business Highlights
08 Aug 2024 //
GLOBENEWSWIRE
Hookipa Doses First Person In HB-500 HIV Treatment Trial
01 Jul 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma: Updated Phase 2 Oncology Data At ASCO 2024 Meeting
04 Jun 2024 //
GLOBENEWSWIRE
HOOKIPA To Host Call On HB-200 Data At ASCO 2024
30 May 2024 //
GLOBENEWSWIRE
Hookipa Positive Clinical Data: To Be Presented At Asco 2024
23 May 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Q1 2024 Financials And Business Highlights
09 May 2024 //
GLOBENEWSWIRE
HOOKIPA Announces Pivotal Ph2/3 Trial Design For HB-200 + Pembrolizumab
25 Apr 2024 //
GLOBENEWSWIRE
HOOKIPA`s HB-700 IND Cleared for KRAS-Mutant Cancers
24 Apr 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
10 Apr 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
22 Mar 2024 //
GLOBENEWSWIRE
HOOKIPA Pharma Announces FDA Clearance of its Investigational NDA for HB-500
20 Nov 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200
22 Oct 2023 //
GLOBENEWSWIRE
HOOKIPA announces publication of data of HBV vaccine developed with Gilead
18 Oct 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200
31 May 2023 //
GLOBENEWSWIRE
HOOKIPA Pharma Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
HOOKIPA doses first patient in trial of HB-400 for chronic hepatitis B
10 May 2023 //
CLINICAL TRIALS ARENA
HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400
09 May 2023 //
GLOBENEWSWIRE
Immunome stops Covid-19 work; Hookipa drops CMV vaccine
16 Mar 2023 //
ENDPTS
Hookipa halts spending on CMV vaccine after seeing phase 2 data
15 Mar 2023 //
FIERCE BIOTECH
HOOKIPA Achieves $5M Milestone Payment from Gilead for Hepatitis B Vaccine
04 Jan 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.